Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
MM-099: Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results From the CC-92480-MM-002 Trial
Irwindeep Sandhu, Paul G. Richardson, Albert Oriol, Darrell White, Richard Leblanc, Noopur Raje, Enrique M. Ocio, Aurore Perrot, Thierry Façon, Cesar Rodriguez, Ralph Wäsch, Meletios A Dimopoulos, Tracy T. Chow, Allison Gaudy, Jing Gong, Zehua Zhou, Tiziana Civardi, Joseph T. Hadala, Yue Zhu, Jessica Katz, Marc S. Raab (2025). MM-099: Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results From the CC-92480-MM-002 Trial. , 25, DOI: https://doi.org/10.1016/s2152-2650(25)02558-3.
Article21 days agoPOSTER: MM-099 Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results From the CC-92480-MM-002 Trial
Irwindeep Sandhu, Paul G. Richardson, Albert Oriol, Darrell White, Richard Leblanc, Noopur Raje, Enrique M. Ocio, Aurore Perrot, Thierry Façon, Cesar Rodriguez, Ralph Wäsch, Meletios A Dimopoulos, Tracy T. Chow, Allison Gaudy, Jing Gong, Zehua Zhou, Tiziana Civardi, Joseph T. Hadala, Yue Zhu, Jessica Katz, Marc S. Raab (2025). POSTER: MM-099 Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results From the CC-92480-MM-002 Trial. , 25, DOI: https://doi.org/10.1016/s2152-2650(25)01219-4.
Article21 days agoEfficacy and safety of isa-vrd in elderly patients with or without frailty criteria: Pooled analysis of imroz and phase 1b studies in newly diagnosed multiple myeloma patients
Enrique M. Ocio, Aurore Perrot, Jesús F. San Miguel, Lionel Karlin, Joaquín Martínez‐López, Sara Bringhen, Paula Rodríguez‐Otero, Mohamad Mohty, Robert Orlowski, Meletios A Dimopoulos, Xavier Leleu, María‐Victoria Mateos, Philippe Moreau, Sandrine Macé, Ercem Kodas, Christina Tekle, Umer Khan, Corina Oprea, Thierry Façon (2025). Efficacy and safety of isa-vrd in elderly patients with or without frailty criteria: Pooled analysis of imroz and phase 1b studies in newly diagnosed multiple myeloma patients. , 146(Supplement 1), DOI: https://doi.org/10.1182/blood-2025-2267.
Article21 days agoLinvoseltamab (LINVO) + carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Initial results from the LINKER-MM2 trial.
Morten Salomo, Enrique M. Ocio, Carmen Martínez‐Chamorro, Sosana Delimpasi, Albert Oriol, Meletios A Dimopoulos, Xavier P. Leleu, Sam Rubinstein, Nisha S. Joseph, Mercedes Gironella, Rajshekhar Chakraborty, Carlos Fernández de Larrea, Aurora Breazna, James Drew, Anita Boyapati, Anasuya Hazra, Glenn S. Kroog, Shawn Sarkaria, Paula Rodríguez‐Otero (2025). Linvoseltamab (LINVO) + carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Initial results from the LINKER-MM2 trial.. , 43(16_suppl), DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.7513.
Article21 days agoLinvoseltamab (LINVO) + Carfilzomib (CFZ) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Initial Results from the LINKER-MM2 Trial
Morten Salomo, Enrique M. Ocio, Carmen Martínez‐Chamorro, Sosana Delimpasi, Albert Oriol, Meletios A Dimopoulos, Xavier Leleu, Samuel M. Rubinstein, Nisha S. Joseph, Mercedes Gironella, Rajshekhar Chakraborty, Carlos Fernández-de Larrea, Aurora Breazna, James Drew, Anita Boyapati, Anasuya Hazra, Glenn S. Kroog, Shawn Sarkaria, Paula Rodríguez‐Otero (2025). Linvoseltamab (LINVO) + Carfilzomib (CFZ) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Initial Results from the LINKER-MM2 Trial. , 25, DOI: https://doi.org/10.1016/s2152-2650(25)03529-3.
Article21 days ago